Trial
NCT05445128
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ensoma
Collaborators
Genetix Biotherapeutics Inc.
Condition
Sickle Cell Disease
Intervention
MGTA-145
Why stopped
This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety issue.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-25